Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Front Immunol. 2021 Nov 19;12:738041. doi: 10.3389/fimmu.2021.738041. eCollection 2021.
CpG-oligodeoxynucleotides (CpG-ODNs) constitute an attractive alternative for asthma treatment. However, very little evidence is available from studies on the oral administration of CpG-ODNs in animals. Previously, we developed acid-resistant particles (named ODNcap) as an oral delivery device for ODNs. Here, we showed that free feeding of an ODNcap-containing feed prophylactically attenuates allergic airway inflammation, hyperresponsiveness, and goblet cell hyperplasia in an ovalbumin-induced asthma model. Using transcriptomics-driven approaches, we demonstrated that injury of pulmonary vein cardiomyocytes accompanies allergen inhalation challenge, but is inhibited by ODNcap feeding. We also showed the participation of an airway antimicrobial peptide (Reg3γ) and fecal microbiota in the ODNcap-mediated effects. Collectively, our findings suggest that daily oral ingestion of ODNcap may provide preventive effects on allergic bronchopulmonary insults regulation of mechanisms involved in the gut-lung connection.
CpG-寡脱氧核苷酸（CpG-ODNs）是一种有吸引力的哮喘治疗替代物。然而，关于动物口服 CpG-ODNs 的研究证据非常有限。此前，我们开发了耐酸颗粒（称为 ODNcap）作为 ODN 的口服递送装置。在这里，我们表明，ODNcap 饲料的自由喂养可预防地减轻卵清蛋白诱导的哮喘模型中的过敏气道炎症、高反应性和杯状细胞增生。使用转录组学驱动的方法，我们证明了肺静脉心肌细胞的损伤伴随着过敏原吸入挑战，但被 ODNcap 喂养所抑制。我们还表明，气道抗菌肽（Reg3γ）和粪便微生物群参与了 ODNcap 介导的作用。总的来说，我们的研究结果表明，每天口服摄入 ODNcap 可能对过敏支气管肺损伤具有预防作用，并调节涉及肠道-肺部连接的机制。
